Obesity

all catalysts(0)

nothing on the calendar yet

News(7)

• Opinion: The podcast telling the stories behind Ambien, Ozempic, EpiPens, and other game-changing drugs
  “We're basically not using our body as directed,” says "Drug Story" host Thomas Goetz.
  stat · 2mo ago
• STAT+: Up and down the ladder: The latest comings and goings
  From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
  stat · 2mo ago
• Lilly tumbles on Foundayo’s shaky week; FDA to issue vouchers for psychedelics
  <figure><div><img src="https://imgproxy.divecdn.com/idsdMAHsPbXObDUtQW2qRG7uveBUVv6HCTn9NTtlDOI/g:nowe:0:0/c:1207:682/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0x…
  biopharma_dive · 2mo ago
• STAT+: Pharmalittle: We&#8217;re reading about a Trump deal with Regeneron, reclassifying medical marijuana, and more
  President Trump heralded a drug-pricing agreement with Regeneron, closing the last of 17 deals sought by the White House
  stat · 2mo ago
• A CAR-T biotech&#8217;s dramatic turnaround, and drugmakers&#8217; tactics to drive more scripts
  This week on "The Readout LOUD": a CAR-T biotech's dramatic turnaround, and drugmakers' tactics to drive more scripts. Listen now.
  stat · 2mo ago
• STAT+: Legislatures in Colorado and Virginia resist moves to constrain drug affordability boards
  Legislators in two states are resisting efforts to restrict prescription drug affordability boards.
  stat · 2mo ago
• Roche, facing biosimilar threats, puts faith in new cancer and obesity drugs
  <p>On a conference call, executives claimed that a closely watched breast cancer pill and portfolio of weight loss medicines could bank more than $9 billion annually.</p>
  biopharma_dive · 2mo ago